A hypersensitivity reaction was the only adverse event reported by > 5% of patients during vedolizumab treatment (4 patients; 5.8%) and a cutaneous reaction was the only adverse event reported by > 5% of patients during anti-TNFα treatment (6 patients; 5.7%). Here, TNF is linked to hypersensitivity reaction disease.